Archways Educational Resource and Support Program
Archways is a convenient educational resource and support program for patients who have been prescribed inhaled or oral treprostinil and their caregivers. Archways offers useful information about your condition and treatment - plus it gives you the opportunity to talk one-on-one with a United Therapeutics Patient Educator over the phone or via video chat.
United Therapeutics and the Archways program do not provide medical advice. You are advised to consult with your Healthcare Provider with any specific questions or concerns about your treatment.
UT ASSIST Access Solutions and Support Team
United Therapeutics has established the ASSIST, Access Solutions and Support Team, program to help patients and customers navigate questions about access to UT medicines. ASSIST also serves as a single point of contact to ensure efficient and timely distribution of our medicines. ASSIST provides support for the following:
- Financial Assistance
- Patient Resources
My Old Meds
As part of United Therapeutics’ unwavering commitment to protecting the global environment, we are working with the Pharmaceutical Product Stewardship Work Group (PPSWG) to help patients securely store and dispose of unwanted, unused, or expired prescription and over-the-counter medicines through a program called MyOldMeds.com.
The MyOldMeds.com website provides information about taking medicines as prescribed, tips for storing medicine securely, and disposing of medicines in specially designed kiosks. The Kiosk Site Locator on MyOldMeds.com provides a map of kiosk sites located in pharmacies and law enforcement locations throughout the U.S. that you can visit to safely dispose of medicines. Information found on MyOldMeds.com will be updated on a regular basis.
PPSWG has compiled the list of kiosk sites based on publicly available information for your convenience but does not guarantee the accuracy of any of the information. PPSWG does not endorse and denies any responsibility or liability for the kiosk sites listed, or for processes they employ for collection, transportation, treatment or disposal of the medicines they collect.
United Therapeutics Corporation Expanded Access Program for an Investigational Drug
Expanded access, also known as compassionate use, may be an option for a limited number of individuals with serious or life-threatening conditions, who have exhausted all available medical options and do not qualify for a clinical trial. In such rare cases, regulators may grant permission for United Therapeutics to provide a treating physician with an unapproved drug for that patient. It is important, however, to remember that investigational drugs have not yet received local regulatory authority approval; potential risks and benefits have not yet been established. Doctors and patients should consider all possible benefits and risks when seeking expanded access to an unapproved product.
In making decisions about expanded access, United Therapeutics considers the patient’s case and the available medical and scientific information about the investigational medicine, while ensuring that expanded access is administered ethically, maintaining fairness, promoting good, and minimizing the risk of harm for both current and future patients.
- A treating physician, on behalf of a specific patient, must submit a request to United Therapeutics on their own accord.
- This request should include the information identified below and should be emailed to email@example.com
- Once United Therapeutics has received the request and all requested information, we will acknowledge receipt of the request within seven (7) business days.
- The request will then be routed for review by the United Therapeutics Expanded Access Review Committee.
- If the request is approved by United Therapeutics, the country regulatory authority will need to grant final approval before the investigational medicine can be shipped to the requesting physician.
- The patient has a sufficiently serious or immediately life-threatening illness with no comparable or satisfactory alternative therapies.
- The patient’s physician has determined that there is no comparable or satisfactory therapy, either approved or investigational, available to diagnose, monitor, or treat the patient’s disease or condition (e.g., due to geographical or entry-related constraints).
- The patient has a disease for which there is sufficient evidence that a clinically meaningful benefit may be expected (i.e., available scientific evidence taken as a whole, provides a reasonable basis to conclude that the drug may be effective) from the use of the investigational medicine, and the benefits outweigh the known or anticipated risks.
- Sufficient evidence of safety indicating that patients in the specific patient population would not be exposed to unreasonable risk if provided the medicine.
- The investigational medicine is currently in clinical development - that is, it is currently being studied in humans and the patient is unable to obtain the investigational drug under an IND or participate in a clinical trial.
- Providing the investigational medicine for the requested use will not interfere with the initiation, conduct, or completion of clinical trials or with the sustainable and equitable access to other patients who do not have alternative treatment options.